Workflow
中国医疗集团(08225) - 2023 - 中期财报
C HEALTH GPC HEALTH GP(HK:08225)2023-08-14 11:51

Financial Performance - For the six months ended June 30, 2023, the group recorded operating revenue of approximately RMB 15,024,938, an increase of about 133% compared to the average of RMB 6,545,000 for the first half of 2022, but a decrease of approximately 50.4% compared to the same period in 2022, which was RMB 30,299,000[3]. - The group reported a profit before tax of approximately RMB 6,854,000, a reduction in loss of about 186.6% compared to the average loss of RMB 7,913,000 in the first half of 2022, but a decrease of approximately 64.3% compared to the same period in 2022, which was RMB 19,117,000[3]. - The gross profit for the six months ended June 30, 2023, was RMB 9,686,000, with a gross profit margin of approximately 65%, compared to a gross profit of RMB 22,637,000 and a margin of approximately 74.7% in the same period of 2022[3]. - The net profit for the six months ended June 30, 2023, was RMB 5,826,000, compared to RMB 16,250,000 for the same period in 2022[7]. - Total revenue for the six months ended June 30, 2023, decreased by 50% compared to the same period in 2022, with PMS revenue also declining by approximately 50%[23]. - Basic earnings per share for the period were approximately RMB 5,826,000, down from RMB 16,250,000 in the same period of 2022[25]. - The basic and diluted earnings per share for the six months ended June 30, 2023, were both 0.6 cents, compared to 1.63 cents for the same period in 2022[7]. Assets and Liabilities - As of June 30, 2023, the group’s non-current assets amounted to RMB 2,160,000, an increase from RMB 1,399,000 as of December 31, 2022[10]. - Current assets totaled RMB 188,428,000 as of June 30, 2023, compared to RMB 177,226,000 as of December 31, 2022[10]. - The net current assets increased to RMB 145,549,000 as of June 30, 2023, from RMB 140,484,000 as of December 31, 2022[10]. - Trade receivables as of June 30, 2023, totaled RMB 117,748,000, compared to RMB 117,032,000 as of December 31, 2022[29]. - Trade payables as of June 30, 2023, amounted to RMB 20,534,000, an increase from RMB 11,524,000 in the same period of 2022[30]. Dividends - The board of directors recommended not to declare any dividend for the six months ended June 30, 2023[3]. - The company has not proposed any dividend for the current period, consistent with the previous year[27]. - The board does not recommend the distribution of dividends for the six months ended June 30, 2023[47]. Administrative and Employee Costs - Administrative expenses increased by 28.14% compared to the same period in 2022, amounting to RMB 1,052,000 for the six months ended June 30, 2023[24]. - The total administrative and employee costs for the period were approximately RMB 2,878,000, compared to RMB 3,646,000 in the same period last year[38]. - As of June 30, 2023, the total number of employees in the group is 40, with total salaries for employees and directors approximately RMB 1,826,000, a decrease from RMB 2,825,000 in the same period of 2022[62]. - The group closely monitors employee compensation and benefits, rewarding employees based on performance and market conditions[61]. - The company has provided various employee benefits, including medical and pension contributions, as well as training and development opportunities[62]. Corporate Governance - The company adhered to the corporate governance practices as per the GEM Listing Rules, with a noted deviation regarding the separation of roles between the chairman and CEO, as the company has not appointed a CEO[91]. - The audit committee, consisting of three independent non-executive directors, reviewed the unaudited consolidated results for the period and confirmed compliance with applicable accounting standards[94]. - The company maintained sufficient public float as of the announcement date, ensuring adequate public shareholding[95]. Future Plans and Strategies - The company aims to become a leader in real-world clinical research services, focusing on five major disease areas[33]. - The group is leveraging real-world data (RWD), real-world studies (RWS), and artificial intelligence (AI) as core capabilities to achieve its business vision[33]. - The company plans to consider raising funds through bank loans, issuing new shares, convertible notes, or new bonds to meet long-term funding needs for operations and future development[40]. - The company aims to leverage its advantages in Hainan to attract new clients, especially in the context of the Hainan Free Trade Zone by 2025, which will facilitate faster market entry for foreign innovative drugs[42]. - The company is focusing on clinical research services for traditional Chinese medicine, capitalizing on favorable policies and a market potential exceeding RMB 1 trillion[44][45]. - The company is implementing a CRSO model to enhance product visibility and corporate reputation through compliant clinical research, aiming for significant business growth[46]. Stock Option Plan - The company has implemented a stock option plan, granting stock options to qualified participants[63]. - The stock option plan was approved on June 30, 2015, with a validity period of 10 years, expiring on June 29, 2025[74]. - The maximum number of shares available for subscription under the stock option plan is 78,087,166 shares, representing 7.85% of the total issued shares as of the interim report date[79]. - The total limit for shares issued upon exercise of all options under the stock option plan and any other plans cannot exceed 30% of the issued shares[77]. - The exercise price of stock options must not be lower than the highest of the closing price on the grant date or the average closing price over the five trading days preceding the grant date[75]. - Each eligible participant must pay HKD 1.00 upon accepting an option offer, which must be paid within 21 days of the offer[84]. - The total number of options granted during the period was 25,500,000, with 25,380,000 remaining after accounting for cancellations[89]. - There are no performance targets that must be met before exercising the options unless decided by the board[80]. - The options granted to independent non-executive directors can be exercised immediately from March 24, 2021, while others have a one-year restriction[89]. - The maximum number of shares that can be issued to each eligible participant in any 12-month period cannot exceed 1% of the issued shares without shareholder approval[79]. - The stock option plan aims to incentivize participants to contribute to the long-term development of the group[75]. Taxation - The applicable income tax rate for the period was between 9% and 25%, with some subsidiaries benefiting from a reduced rate of 15% due to tax incentives[26]. Other Information - There were no significant investments or capital commitments during the period, and the company had no major acquisitions or disposals of subsidiaries[48][49][50]. - The company has not purchased, sold, or redeemed any of its listed shares during the reporting period[65]. - As of June 30, 2023, Mr. Guo Xia holds 132,851,941 shares, representing 13.35% of the company, and has control over 590,716,637 shares, representing 59.35%[68]. - The company has not disclosed any competitive interests from directors or management shareholders as of June 30, 2023[66]. - No other individuals hold interests or short positions in the company's shares or underlying shares as of June 30, 2023[72]. - There have been no significant subsequent events from June 30, 2023, to the date of this announcement[60].